Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases

IntroductionIxekizumab is a biologic agent primarily indicated for the treatment of moderate to-severe plaque psoriasis. This study aimed to evaluate the post-marketing safety profile of ixekizumab by analyzing adverse event (AE) reports retrieved from the Food and Drug Administration Adverse Event...

Descripció completa

Dades bibliogràfiques

Autors principals:	Kaidi Zhao, Xuanfeng Tan, Miao Qin, Qinxiao Li, Qinqin Meng, Ying Liu, Jing Li, Jiashu Liu
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2025-10-01
Col·lecció:	Frontiers in Medicine
Matèries:	ixekizumab biologics psoriasis FAERS disproportionality analysis adverse events
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fmed.2025.1652401/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!